isoxazoles has been researched along with Basal Ganglia Diseases in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (44.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stahl, SM | 1 |
| Graff-Guerrero, A; Kapur, S; Mamo, DC; Mulsant, BH; Pollock, BG; Uchida, H | 1 |
| Bossie, CA; Canuso, CM; Carothers, J; Damaraju, CV; Dirks, B; Kalali, AH; Kosik-Gonzalez, C; Mahmoud, R; Zhu, Y | 1 |
| Eerdekens, M; Hough, D; Kramer, M; Lane, R; Lim, P; Litman, R; Liu, Y | 1 |
| Asada, T; Mizukami, K; Sato, S | 1 |
| Eerdekens, M; Gassmann-Mayer, C; Gopal, S; Hough, D; Lim, P; Nasrallah, HA; Quiroz, JA; Yuen, E | 1 |
| English, C; Harrington, CA | 1 |
| Weiden, PJ | 1 |
| Fukuda, M; Iga, T; Nakashima, Y; Ohno, Y; Sato, H; Sawada, Y; Takayanagi, R; Tsuchiya, F; Yamada, Y | 1 |
| Möller, HJ; Müller, N; Müller-Arends, A; Riedel, M; Schwarz, MJ; Spellmann, I; Strassnig, M; Weber, K; Zach, J | 1 |
| Goto, M; Kaji, K; Kakihara, S; Matsumoto, C; Nakamura, J; Ohmori, O; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R | 1 |
| Kapur, S; Labelle, A; Mamo, D; Mann, S; Mannaert, E; Reiss, J; Remington, G; Shammi, C | 1 |
| Cutler, AJ; Polymeropoulos, MH; Weiden, PJ; Wolfgang, CD | 1 |
| Heinrich, K; Hruschka, H; Kinzler, E; Klieser, E; Lehmann, E | 1 |
| Breier, A | 1 |
| Pickar, D | 1 |
| Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR | 1 |
| Houle, S; Kapur, S; Remington, G; Wilson, AA; Zipursky, RB | 1 |
| Ballard, CG; Harrison, RW; McKeith, IG | 1 |
| Conway, PG; Corbett, R; Cornfeldt, M; Rush, DK; Strupczewski, JT; Szewczak, MR; Wilmot, CA | 1 |
| Buttiëns, M; Dierick, G; Geutjens, J; Heylen, S; Sieben, G; Thiry, P; Vanden Borre, R; Vermote, R | 1 |
| Cesková, E; Svestka, J | 1 |
| Cai, J; Hartman, HB; Kerman, LL; Kongsamut, S; Roehr, JE; Sandrasagra, A; Tang, L; Weissensee, P | 1 |
| Ancione, M; Avenoso, A; Facciolà, G; Madia, AG; Perucca, E; Salemi, M; Scordo, MG; Spina, E | 1 |
| Gerlach, J | 1 |
6 review(s) available for isoxazoles and Basal Ganglia Diseases
| Article | Year |
|---|---|
Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia | 2010 |
Iloperidone for the treatment of schizophrenia: an updated clinical review.
Topics: Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Hospitalization; Humans; Isoxazoles; Piperidines; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2012 |
Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Humans; Isoxazoles; Long QT Syndrome; Male; Middle Aged; Patient Dropouts; Piperidines; Prospective Studies; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain | 2008 |
Serotonin, schizophrenia and antipsychotic drug action.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Isoxazoles; Piperazines; Piperidines; Risperidone; Schizophrenia; Serotonin; Tryptophan | 1995 |
Prospects for pharmacotherapy of schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Isoxazoles; Piperidines; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia | 1995 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors, Dopamine; Receptors, Glutamate; Receptors, Neurotransmitter; Receptors, Serotonin; Remoxipride; Risperidone; Schizophrenia; Serotonin Antagonists; Sulpiride | 1991 |
10 trial(s) available for isoxazoles and Basal Ganglia Diseases
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Quetiapine Fumarate; Schizophrenia; Severity of Illness Index; Young Adult | 2009 |
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2010 |
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Body Mass Index; Body Weight; Case-Control Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Delivery Systems; Evidence-Based Medicine; Female; Humans; Injections; Isoxazoles; Kaplan-Meier Estimate; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2010 |
Risperidone plasma levels, clinical response and side-effects.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Female; Genotype; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prospective Studies; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia | 2005 |
Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Double-Blind Method; Electrocardiography; Electroencephalography; Female; Humans; Infant, Newborn; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia, Paranoid | 1994 |
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1995 |
Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Intellectual Disability; Isoxazoles; Male; Mental Disorders; Middle Aged; Piperidines; Placebos; Risperidone | 1993 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Male; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure Liquid; Chronic Disease; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 2001 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors, Dopamine; Receptors, Glutamate; Receptors, Neurotransmitter; Receptors, Serotonin; Remoxipride; Risperidone; Schizophrenia; Serotonin Antagonists; Sulpiride | 1991 |
10 other study(ies) available for isoxazoles and Basal Ganglia Diseases
| Article | Year |
|---|---|
Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Humans; Isoxazoles; Piperidines; Serotonin 5-HT2 Receptor Antagonists | 2013 |
Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Case-Control Studies; Cross-Sectional Studies; Dopamine Antagonists; Female; Humans; Isoxazoles; Male; Middle Aged; Ontario; Paliperidone Palmitate; Positron-Emission Tomography; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrimidines; Raclopride; Receptors, Dopamine D2; Risperidone; Schizophrenia; Treatment Outcome | 2009 |
Successful treatment of extrapyramidal and psychotic symptoms with zonisamide in a patient with dementia with Lewy bodies.
Topics: Aged; Basal Ganglia Diseases; Female; Humans; Isoxazoles; Lewy Body Disease; Psychotic Disorders; Treatment Outcome; Zonisamide | 2010 |
Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Humans; Isoxazoles; Models, Biological; Paliperidone Palmitate; Pyrimidines; Receptors, Dopamine D2; Risperidone | 2002 |
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catecholamines; Central Nervous System Stimulants; Cotinine; Cues; Cytochrome P-450 CYP2D6; Female; Homovanillic Acid; Humans; Isoxazoles; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paliperidone Palmitate; Polymorphism, Genetic; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Smoking | 2005 |
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Corpus Striatum; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Positron-Emission Tomography; Prolactin; Psychotic Disorders; Pyrimidines; Raclopride; Receptors, Dopamine D2; Risperidone; Schizophrenia | 2006 |
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Humans; Isoxazoles; Male; Piperidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed | 1995 |
Neuroleptic sensitivity to risperidone in Lewy body dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Female; Humans; Isoxazoles; Lewy Bodies; Male; Middle Aged; Parkinson Disease; Piperidines; Risperidone | 1995 |
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Clozapine; Dopamine Antagonists; Haloperidol; Isoxazoles; Male; Mice; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Risperidone; Saimiri; Serotonin Antagonists | 1995 |
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; CHO Cells; Cricetinae; Humans; Isoxazoles; Kinetics; Piperidines; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4; Receptors, Dopamine D5; Receptors, Serotonin | 1996 |